The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...
Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move ...
Hosted on MSN
Next-gen CAR-T cell therapy shows early promise in patients with refractory B-cell acute lymphoblastic leukemia
Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational next-generation CD19-directed CAR-T cell therapy that is manufactured in 48 hours using ...
(RTTNews) - MaxCyte, Inc. (MXCT), a cell-engineering technology company, announced on Wednesday that it has entered into a strategic platform license or SPL agreement with TG Therapeutics, Inc. (TGTX) ...
A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback